A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
A phase 1/2 trial of IOV-4001 in melanoma and non-small-cell lung cancer, run by Iovance Biotherapeutics, Inc., now recruiting.
Overview
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer is a phase 1/2 interventional study registered as NCT05361174 by Iovance Biotherapeutics, Inc., with 53 participants planned, started 2022-07-20 and due to reach its primary completion in 2027-09. Interventions recorded: IOV-4001.
Similar pages
not linked directly; found by shared links- TrialAutologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Shares Iovance Biotherapeutics, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Shares Iovance Biotherapeutics, Melanoma and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
- TrialSafety and Efficacy of OBX-115 in Advanced Solid Tumors
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
- TrialDose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy of GV20-0251 in Participants With Solid Tumor Malignancies
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
- TreatmentBA3071
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.